Ensign Peak Advisors
LENZ icon

Ensign Peak Advisors’s LENZ Therapeutics LENZ Stock Holding History

Ensign Peak Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,275
Closed -$1.24M – 1739
2025
Q4 		$1.24M Hold
77,275
– – ﹤0.01% 779
2025
Q3 		$3.6M Hold
77,275
– – 0.01% 665
2025
Q2 		$2.26M Hold
77,275
– – ﹤0.01% 857
2025
Q1 		$1.99M Buy
+77,275
New +$1.9M ﹤0.01% 899

Other funds holding LENZ

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Ensign Peak Advisors's LENZ Position: Q1 2026 in Review

Ensign Peak Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 77,275 shares — an estimated $1.24M sold.

Ensign Peak Advisors first reported a position in LENZ in Q1 2025 and held it in 4 quarters. The position peaked at $3.6M in Q3 2025. 146 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Ensign Peak Advisors reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 77,275 LENZ Therapeutics shares in Q1 2026, an estimated $1.24M.
  • Ensign Peak Advisors first reported a position in LENZ Therapeutics in Q1 2025 and held it in 4 quarters.
  • Ensign Peak Advisors's LENZ Therapeutics position peaked at $3.6M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.